Screener
Alnylam Pharmaceuticals ALNY Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.8%-4.1pp | 81%-5.3pp | 81.8%-4.6pp | 84%-2.8pp | 83.9%-4.5pp | |
| Operating margin | 20.8%+28.1pp | 17.5%+22.5pp | 13.5%+21.4pp | 8.2%+17.2pp | -7.3%-11.7pp | |
| Net margin | 15.3%+26.6pp | 11.7%+21.5pp | 7.5%+19.9pp | 2.6%+18.4pp | -11.4%-8.3pp | |
| Returns | ||||||
| Return on equity | 91.4%— | 84.4%— | 65%— | 62.2%— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.4× | 0.9×+0.3× | 0.8×+0.2× | 0.7×+0.2× | 0.6×-0.1× | |
| Liquidity | ||||||
| Current ratio | 3.1×+0.3× | 3.1×+0.1× | 2.8×0.0× | 2.5×-0.2× | 2.8×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.9× | 0.2×-2.1× | 0.3×-3.7× | 1.1×-7.5× | 1.1×— | |
| Net debt / EBITDA | -1.4×— | -1.8×— | -2.5×— | -3.8×— | —— | |
| Per Share | ||||||
| Book value per share | $9.79+410% | $7.78+774% | $5.86+1,015% | $1.70+577% | $1.92+8,027% | |
| Valuation | ||||||
| Market capitalization | $30.04B-49.8% | $43.88B+25.6% | $52.54B+73.1% | $59.77B+69.3% | $42.38B+37.9% | |
| Price / earnings | 41×-682× | 87.4×— | 188.9×— | 721.9×— | —— | |
| Price / sales | 6.3×-12.4× | 10.2×-4.6× | 14.1×+0.6× | 18.6×+1.8× | 17.2×+4.1× | |
| Price / book | 22.2×-234× | 40.8×-262× | 66.6×-386× | 255.6×-836× | 169.1×— | |
| EV / EBITDA | 27.1×-156× | 52.6×— | 91.8×— | 182.4×— | —— |
FAQ
- What are Alnylam Pharmaceuticals's profit margins?
- Alnylam Pharmaceuticals (ALNY) runs a 79.8% gross margin and a 20.8% operating margin, with a 15.3% net margin.
- Where do Alnylam Pharmaceuticals's ratios come from?
- Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
